Comment on: Indications for Thoracic Endovascular Aortic Repair (TEVAR): A Brief Review by Frank Manetta, MD, Joshua Newman, MS, Allan Mattia, MD. *Int J Angiol* 2018; 28:177–184

Patrick Bohan¹

¹ Department of Clinical and Medical Affairs, Terumo Aortic, Sunrise, Florida

Int J Angiol 2019;28:151–152.

Address for correspondence Patrick Bohan, BA, MLitt, Department of Clinical and Medical Affairs, Terumo Aortic, 799 International Parkway, Sunrise, FL 33325 (e-mail: p.bohan@terumo-aortic.com).

I appreciated the broad review by Dr. Manetta and colleagues of developments and devices for thoracic endovascular repair (TEVAR).¹ The authors did not include the Relay stent-graft (Terumo Aortic, formerly Bolton Medical, Sunrise, FL). This device was developed to treat thoracic aortic pathologies, specifically thoracic aortic aneurysms (TAA), pseudoaneurysms, penetrating atherosclerotic ulcers (PAU), dissection, transection, and intramural hematoma (IMH) in adult patients and has been reviewed in the literature.² Relay is currently approved in the US for the treatment of TAAs and PAUs. Published results show low rates of stroke, endoleak, and reintervention.^{3–5} The device is available in bare stent and nonbare stent (NBS) configurations. A low-profile configuration (19–23 Fr, RelayPro) received the Conformité Européenne (CE) mark in 2018. Furthermore, scalloped and branched configurations of Relay allow for treatment of aortic arch lesions.^{6–8}

References

- 1 Manetta F, Newman J, Mattia A. Indications for thoracic endovascular aortic repair (TEVAR): a brief review. *Int J Angiol* 2018;27(04):177–184
- 2 Khayat M, Cooper KJ, Khaja MS, Gandhi R, Bryce YC, Williams DM. Endovascular management of acute aortic dissection. *Cardiovasc Diagn Ther* 2018;8(Suppl 1):S97–S107
- 3 Farber MA, Lee WA, Szeto WY, Panneton JM, Kwolek CJ. Initial and midterm results of the Bolton Relay thoracic aortic endovascular pivotal trial. *J Vasc Surg* 2017;65(06):1556–1566.e1
- 4 Riambau V, Zipfel B, Coppi G, et al; RELAY Endovascular Registry for Thoracic Disease RESTORE Investigators. Final operative and midterm results of the European experience in the RELAY Endovascular Registry for Thoracic Disease (RESTORE) study. *J Vasc Surg* 2011;53(03):565–573
- 5 Zipfel B, Zaefferer P, Riambau V, et al; RESTORE II Study Group. Worldwide results from the RESTORE II on elective endografting of thoracic aneurysms and dissections. *J Vasc Surg* 2016;63(06):1466–1475
- 6 Czerny M, Schmidli J, Adler S, et al. Current options and recommendations for the treatment of thoracic aortic pathologies involving the aortic arch: an expert consensus document of the European Association for Cardio-Thoracic Surgery (EACTS) & the European Society for Vascular Surgery (ESVS). *Eur J Vasc Endovasc Surg* 2018; (e-pub ahead of print). . Doi: 10.1016/j.ejvs.2018.09.016
- 7 Makaloski V, Tsilimparis N, Rohlfes F, Heidemann F, Debus ES, Kölbel T. Endovascular total arch replacement techniques and early results. *Ann Cardiothorac Surg* 2018;7(03):380–388
- 8 Rudarakanchana N, Jenkins MP. Hybrid and total endovascular repair of the aortic arch. *Br J Surg* 2018;105(04):315–327

Mr. Bohan's ORCID is <http://orcid.org/0000-0002-1148-2645>.

published online
March 2, 2019

Copyright © 2019 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
Tel: +1(212) 584-4662.

DOI <https://doi.org/10.1055/s-0039-1679872>.
ISSN 1061-1711.

Author's Rebuttal

Frank Manetta, MD, FICA¹

¹Department of Cardiovascular and Thoracic Surgery at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York

Address for correspondence Frank Manetta, MD, FICA, Department of Cardiovascular and Thoracic Surgery, Southside Hospital, 301 East Main Street, 2 North, Bay Shore, NY 11706 (e-mail: fmanetta@northwell.edu).

We would like to thank Mr. Bohan for his comment as well as acknowledge the significance of the Bolton Relay device with Plus Delivery System.

As mentioned, the device has been demonstrated safe for utilization both with penetrating atherosclerotic ulcers (PAU) and descending thoracic aortic aneurysms (TAA) in the Bolton Relay Thoracic Aortic Endovascular Pivotal Trial demonstrating 5-year freedom from all-cause mortality as

high as 57% compared with 50.2% ($p = 0.289$) in the surgical arm. With the improved Plus Delivery System, the Bolton Relay device is a considerable option for endovascular management of both TAAs and PAUs and may be considered for additional aortic pathologies as well. As with all current endovascular devices, long-term efficacy remains to be demonstrated and continued research will help to elucidate the longevity of endovascular interventions. Thank you.